Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with ...

The platinum chemotherapy shortage, first announced on Feb. 10, 2023, resulted in a modest absolute reduction in platinum use ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

AIC-100 is under clinical development by AffyImmune Therapeutics and currently in Phase I for Anaplastic Thyroid Cancer.

Treprostinil is under clinical development by United Therapeutics and currently in Phase III for Idiopathic Pulmonary Fibrosis.

At the American Society of Hematology annual meeting, a roundtable discussion highlighted the evolving role of minimal residual disease (MRD) as a treatment endpoint in multiple myeloma, exploring its ...

The FDA has approved tislelizumab plus chemotherapy for the treatment of patients with newly diagnosed, locally advanced or ...

Through interviews and articles infused with expert insight, progress against this cancer that develops in the bone marrow ...

Recently, omission of axillary lymph node dissection among patients with early breast cancer has been found to have no ...

The following is a summary of “Oncologic outcomes for invasive squamous cell carcinoma with a clinically resolved biopsy site ...

Oncologists want definitive guidance on whether patients with resectable NSCLC benefit from immunotherapy before and after ...

Although the primary endpoint was not met in a phase 2 study of women who used CBD before a scan, researchers say CBD does ...